Immix Biopharma在ASH 2025口头报告中公布了Nxc-201第二阶段的积极结果,向BLA提交迈进,这一疗法有望成为复发/难治性AL淀粉样变性患者的一流且最佳治疗选择。
Immix Biopharma在ASH 2025口头报告中公布了Nxc-201第二阶段的积极结果,向BLA提交迈进,这一疗法有望成为复发/难治性AL淀粉样变性患者的一流且最佳治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.